【制药网 医药股市】3月5日,港股医药板块表现活跃,在多重行业政策利好加持下,创新药服务赛道表现突出。截至收盘,维亚生物、凯莱英、康龙化成、泰格医药等多家CRO/CDMO 企业收涨。消息面上,近期医药行业迎来多重政策利好,如国家药监局明确“十五五”期间大力支持生物制造产业创新发展;工信部等八部门联合印发《中药工业高质量发展实施方案(2026—2030年)》;《国家基本药物目录管理办法》正式出台;1...
Source Link【制药网 医药股市】3月5日,港股医药板块表现活跃,在多重行业政策利好加持下,创新药服务赛道表现突出。截至收盘,维亚生物、凯莱英、康龙化成、泰格医药等多家CRO/CDMO 企业收涨。消息面上,近期医药行业迎来多重政策利好,如国家药监局明确“十五五”期间大力支持生物制造产业创新发展;工信部等八部门联合印发《中药工业高质量发展实施方案(2026—2030年)》;《国家基本药物目录管理办法》正式出台;1...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.